There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report) and SAGE Therapeutics (SAGE – Research Report) with bullish sentiments.
Anavex Life Sciences (AVXL)
Dawson James analyst Jason Kolbert maintained a Buy rating on Anavex Life Sciences on October 15 and set a price target of $16.00. The company’s shares closed last Friday at $4.84.
According to TipRanks.com, Kolbert ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.9% and a 37.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, OncoSec Medical, and Mesoblast.
Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $13.33.
SAGE Therapeutics (SAGE)
J.P. Morgan analyst Cory Kasimov maintained a Buy rating on SAGE Therapeutics on October 15. The company’s shares closed last Friday at $69.09.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 20.3% and a 55.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $71.42 average price target, a 7.8% upside from current levels. In a report issued on October 6, RBC Capital also maintained a Buy rating on the stock with a $75.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.